Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.
- Ethics approval granted by Bellberry HREC for Phase 1 oral liquid study
- Trial to enrol 32 healthy volunteers assessing pharmacokinetics and safety
- Oral liquid designed to improve administration flexibility for ALS patients
- Study supports broader NUZ-001 clinical and regulatory development
- Trial initiation targeted for Q3 2026 with completion in Q4
Ethics Approval Advances NUZ-001 Oral Liquid Development
Neurizon Therapeutics (ASX:NUZ) has cleared a significant hurdle with the Bellberry Human Research Ethics Committee approving its Phase 1 clinical study for the NUZ-001 oral liquid formulation. This milestone underpins the biotech’s strategy to enhance treatment options for amyotrophic lateral sclerosis (ALS) patients, particularly addressing the challenge of swallowing difficulties that worsen as the disease progresses.
The oral liquid formulation aims to improve treatment accessibility and administration flexibility, allowing patients to maintain continuity of care even as dysphagia intensifies. It represents a patient-centred innovation designed to make NUZ-001 more practical for patients, caregivers, and clinical teams alike.
Study Design Targets Pharmacokinetic and Safety Insights
The upcoming Phase 1 trial will enrol 32 healthy volunteers in Australia, employing a randomised, four-arm design to compare the oral liquid against tablet formulations under fed and fasted conditions. The study will collect pharmacokinetic, safety, tolerability, exploratory biomarker, and palatability data to support both regulatory filings and commercial development plans.
This trial complements Neurizon’s ongoing participation in the Phase 2/3 HEALEY ALS Platform Trial in the US, where NUZ-001 is being tested in patients. The oral liquid formulation’s development was first flagged in mid-2025 as part of a broader push to expand NUZ-001’s utility across different disease stages, reflecting a strategic response to patient needs identified during clinical development.
Strategic Context and Upcoming Milestones
Interim Executive Chairman Sergio Duchini emphasised the significance of the ethics approval, highlighting the company’s commitment to patient-centred solutions and the practical challenges faced by ALS patients. The study is slated to start in the third quarter of 2026, with completion expected by year-end, pending operational readiness.
Neurizon’s recent capital raise, which boosted its balance sheet by A$2.7 million, provides financial headroom to advance NUZ-001’s clinical programs, including this formulation study and the pivotal Phase 2/3 trial. This funding boost follows a series of regulatory and clinical milestones, including FDA clearance and trial dosing commencement earlier in 2026, positioning the company for a potentially transformative year in ALS drug development.
Bottom Line?
The Phase 1 study’s progress will be a key indicator of NUZ-001’s adaptability to patient needs, with data expected to shape regulatory and commercial pathways in a challenging therapeutic area.
Questions in the middle?
- How will the pharmacokinetic profile of the oral liquid compare to tablets in ALS patients?
- What impact could improved administration flexibility have on patient adherence and outcomes?
- Will regulatory agencies view the oral liquid formulation as a significant advancement for NUZ-001’s approval prospects?